Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 4, 2003 - Issue 8
Submit an article Journal homepage
230
Views
29
CrossRef citations to date
0
Altmetric
Review

Treatment of bacterial skin and skin structure infections

David RP Guay College of Pharmacy, University of Minnesota, Weaver-Densford Hall 7-115C, 308 Harvard Street SE, Minneapolis, MN 55455, USA
Pages 1259-1275 | Published online: 02 Mar 2005

Bibliography

  • TUNNESSEN WW: A survey of skin disorders seen in pediatric general and dermatology clinics. Pediatr. Dermatel (1984) 1:219–222.
  • HAYDEN GF: Skin diseases encountered in a pediatric clinic: a one-year prospective study. Ant. J. Dis. Child. (1985) 139:36–38.
  • ROTH RR: Microbiology of the skin: resident flora, ecology, infection. J. Am. Acad. Dermatel (1989) 20:367–390.
  • ••Although dated, this is the best review ofskin microbiology and risk factors for infection available.
  • JIA-TAI L, YUAN L, JIE H et al: Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections. Clin. Infect. Dis. (1997) 24:498–505.
  • DREHOBL M, KOENIG L, BARKER M,ST. CLAIR P, MALADORNO D: Fleroxacin 400 mg once daily versus ofloxacin 400 mg twice daily in skin and soft tissue infections. Chemotherapy (1997) 43:378–384.
  • TALAN DA, SUMMANEN PH, FINEGOLD SM: Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse. Clin. Infect. Dis. (2000) 31:464–471.
  • STEVENS DL, SMITH LG, BRUSS JB et al.: Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicreb. Agents Chemether. (2000) 44:3408–3413.
  • TARSHIS GA, MISKIN BM, JONES TM et al.: Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections. Antimicreb. Agents Chemether. (2001) 45:2358–2362.
  • TAN JS, WISHNOW RM, TALAN DA et al.: Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicreb. Agents Chemether. (1993) 37:1580–1586.
  • SMITH JVV, NICHOLS RL: Comparisonof oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections. Am. J. Med. (1993) 94\(Suppl. 341505–1545.
  • POWERS RD: Open trial of oral fleroxacin versus amoxicillin/clavulanate in the treatment of infections of skin and soft tissue. Am. I Med. (1993) 94(Suppl. 3A):1555–1585.
  • TASSLER H: Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections. Am. I Med. (1993) 94(Suppl. 3A):1595–1655.
  • PARISH LC, JUNGKIND DL: Systemic antimicrobial therapy for skin and skin structure infections: comparison of fleroxacin and ceftazidime. Am. J. Med. (1993) 94(Suppl. 3A): 166S–173S.
  • LORIAN V, PAVLETICH K: Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections. Drugs Expt. Clin. Res. (1994) 20:209–214.
  • NOLEN T: Comparative studies of cefprozil in the management of skin and soft-tissue infections. Ear: Clin. Microbial. Infect. Dis. (1994) 13:866–871.
  • AZIMI PH, BARSON WJ, JANNER D, SWANSON R, Unasyn Pediatric Study Group: Efficacy and safety of ampicillin/sulbactam and cefuroxime in the treatment of serious skin and skin structure infections in pediatric patients. Pediatr. Infect. Dis. J. (1999) 18:609–613.
  • PARISH LC, ROUTH HB, MISKIN B et al.: Moidfloxacin versus cephaleidn in the treatment of uncomplicated skin infections. Int. J. Clin. Frac. (2000) 54:497–503.
  • NICHOLS RL, GRAHAM DR, BARRIERE SL et al.: Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Antimicreb. Chemethec (1999) 44:263–273.
  • KRUMPE PE, COHN S, GARRELTES J et al.: Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. J. Antimicreb. Chemether. (1999) 43(Suppl. A):117–128.
  • NICODEMO AC, ROBLEDO JA, JASOVICH A, NETO W: A multicentre, double-blind, randomized study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int. .1. Clin. Frac. (1998) 52:69–74.
  • RODRIGUEZ-NORIEGA E, ESPARZA-AHUMADA S, MORFIN-OTERO R: Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections. Chemether. (1995) 7\(Suppl. 2):155–160.
  • HEBERT AA, STILL JG, REUMAN PD: Comparative safety and efficacy of clarithromycin and cefadroxil suspensions in the treatment of mild to moderate skin and skin structure infections in children. Pediatr. Infect. Dis. J. (1993) 12:S112–S117.
  • AMAYA-TAPIA G, AGUIRRE-AVALOS G, ANDRADE-VILLANUEVA J et al.: Once-daily azithromycin in the treatment of adult skin and skin-structure infections.Antimicreb. Chemether. (1993) 31(Suppl. E):129–135.
  • RODRIGUEZ-SOLARES A, PEREZ-GUTIERREZ F, PROSPERI J, MILGRAM E, MARTIN A: A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. J. Antimicreb. Chemethec (1993) 31 (Suppl. E):103–109.
  • PARISH LC, Clarithromycin Study Group: clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. hat. J. Dermatel (1993) 32:528–532.
  • DERRIENNIC M, ESCANDE JP: Dirithromycin in the treatment of skin and skin structure infections. J. Antimicreb. Chemethec (1993) 31(Suppl. C):159–168.
  • HANFLING MJ, HAUSINGER SA, SQUIRES J: Loracarbef versus cefaclor in pediatric skin and skin structure infections. Pediatr. Infect. Dis. (1992) 11:S27–S30.
  • HESKEL NS, SIEPMAN NC, PICHOTTA PJ, GREEN EM, STOLL RW: Erythromycin versus cefadroxil in the treatment of skin infections. Int. J. Dermatel (1992) 31:131–133.
  • CHIRURGI VA, EDELSTEIN H, OSTER SE et al: Randomized comparison trial of teicoplanin IV, teicoplanin IM, and cefazolin therapy for skin and soft tissue infections caused by Gram-positive bacteria. South Med. J. (1994) 87:875–880.
  • GENTRY LO, RODRIGUEZ-GOMEZ G: Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. Antimicrob. Agents Chemother. (1991) 35:2371–2374.
  • BERNARD P, PLANTIN P, ROGER H et al.: Roxithromycin versus penicillin in the treatment of erysipelas in adults. Br. .1. Dermatol. (1992) 127:155–159.
  • PARISH LC, DOYLE CA, DURHAM SJ, WILBER RB: Cefprozil versus cefaclor in the treatment of mild to moderate skin and skin-structure infections. Cefprozil Multicenter Study Group. Clin. Titer. (1992) 14:458–469.
  • KIANI R: Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections. Eur. Clin. Microbial. Infect. Dis. (1991) 10:880–884.
  • NELDNER KH: Double-blind randomizedstudy of oral temafloxacin and cefadroxil in patients with mild to moderately severe bacterial skin infections. Am. J. Med. (1991) 91(Suppl. 6A):111S–1145.
  • PARISH LC, JUNGKIND DL: Systemic antimicrobial therapy in skin and skin structure infections: comparison of temafloxacin and ciprofloxacin. Am. J. Med. (1991) 91(Suppl. 6A):1155–1195.
  • DEMIDOVICH CW, WITTLER RR, RUFF ME, BASS JW, BROWNING WC: Impetigo. current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am. J. Dis. Child (1990) 144:1313–1315.
  • SCHWARTZ R DAS-YOUNG LR RAMIREZ-RONDA C, FRANK E: Current and future management of serious skin and skin-structure infections. Am. J. Med. (1996) 100(Suppl. 6A):905–955.
  • GRAHAM DR, LUCASTI C, MALAFAIA 0 et al: Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Gin. Infect. Dis. (2002) 34:1460–1468.
  • WILSON SE, SOLOMKIN JS, LE V, CAMMARATA SK, BRUSS JB: A severity score for complicated skin and soft tissue infections derived from Phase III studies of linezolid. Am. J. Surg. (2003) 185:369–375.
  • STULBERG DL, PENROD MA, BLATNY RA: Common bacterial skin infections. Am. Fam. Phys. (2002) 66:119–124.
  • COX NH: Management of lower leg cellulitis. Clin. Med. (2002) 2:23–27.
  • DARMSTADT GL: Bacterial skin infections in adolescents. Adoles. Med. State Art Rev (2001) 12:243–268.
  • ••This is an excellent review of bacterialSSSIs in the adolescent population.
  • HOWARD R: The appropriate use of topical antimicrobials and antiseptics in children. Pediatr. Ann. (2001) 30:219–224.
  • OUMEISH I, OUMEISH OY, BATAINEH 0: Acute bacterial skin infections in children. Clin. Dermatol. (2000) 18:667–678.
  • DAS S, SIMPSON NB: Diagnosing bacterial skin infections. Practitioner (2000) 244:836;838–839;841–842;844;849.
  • MANCINI AJ: Bacterial skin infections in children: the common and the not so common. Pediatr. Ann. (2000) 29:26–35.
  • ROBERTS SA, LANG SD: Skin and soft tissue infections. NZ Medi-. (2000) 113:164–167.
  • KAYE ET: Topical antibacterial agents. Infect. Dis. Clin. N Am. (2000) 14:321–339.
  • •This is the best review of topical agents in SSSIs so far.
  • RHODY C: Bacterial infections of the skin. Prim. Care (2000) 27:459–473.
  • SADICK NS: Current aspects of bacterial infections of the skin. Dermatol. (1997) 15:341–349.
  • CHARTIER C, GROSSHANS E: Erysipelas: an update. Int. J. Dermatol. (1996) 35:779–781.
  • CARROLL JA: Common bacterial pyodermas. Taking aim against the most likely pathogens. Postgrad. Med. (1996) 100( 3):311–313,317-322.
  • GUAY DRP: Pet-assisted therapy in the nursing home setting: potential for zoonosis. Am. .1. Infect. Cont. (2001) 29:178–186.
  • SWARTZ MN: Cellulitis and subcutaneoustissue infections. In: Principles and Practice of Infectious Diseases (Volume 1), Mandell GL, Bennett JE, Dolin R (Eds), Churchill-Livingstone, Philadelphia, PA, USA (2000):1037–1057.
  • SUMMANEN PH, TALAN DA, STRONG C et al: Bacteriology of skin and soft tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin. Infect. Dis. (1995) 20\(Suppl. 2):S279–S282.
  • GERDING DN: Foot infections in diabeticpatients: the role of anaerobes. Gin. Infect. Dis. (1995) 20\(Suppl. 2):5283–5288.
  • •Although dated, this is a superior review of anaerobes in diabetic SSSIs.
  • ARKWRIGHT PD, DANIEL TO, SANYAL D, DAVID TJ, PATEL L: Age-related prevalence and antibiotic resistance of pathogenic staphylococci and streptococci in children with infected atopic dermatitis at a single-specialty center. Arch. Dermatol. (2002) 138:939–941.
  • CRITCHLEY IA, SAHM DF, THORNSBERRY C et al: Antimicrobial susceptibility of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999. Diagn. Microbial. Infect. Dis. (2002): 42:129–135.
  • •An introduction to the LIBRA surveillance network.
  • FINNERTY EF, FOLAN DW Jr: Changing antibiotic sensitivities of bacterial skin diseases. Office practice. 1977-1978. Cutts (1979) 23:227–230.
  • OHANA N, KENESS J, VERNER E et al: Skin-isolated, community-acquired Staphylococcus aureus: in vitro resistance to methicillin and erythromycin. j. Am. Acad. Dermatol. (1989) 21:544–546.
  • DAGAN R BAR-DAVID Y: Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. (1992) 36:287–290.
  • NISHIJIMA S, NAKAGAWA M: Sensitivity of antibacterials of Staphylococcus aureus isolated from impetigo patients. I Int. Med. Re.c. (1997) 25:210–213.
  • NISHIJIMA S, KUROKAWA I: Antimicrobial resistance of Staphylococcus aureus isolated from skin infections. hat. Antimicrob. Agents (2002) 19:241–243.
  • NISHIJIMA S, NAMURA S, MITSUYA K,ASADA Y: The incidence of isolation of methicillin-resistant Staphylococcus aureus (MRSA) strains from skin infections during the past three years (1989-1991). Dermatol. (1993) 20:193–197.
  • NISHIJIMA S, NAMURA S, NAKAGAWA M, KUROKAWA I, KAWABATA S: Sensitivity of antibacterials of Staphylococcus aureus isolated in different types of skin infections. J. mt. Med. Res. (1997) 25:1–7.
  • GALES AC, JONES RN, PFALLER MA, GORDON KA, SADER HS: Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTRY Study Group. Int. J. Infect. Dis. (2000) 4:75–84.
  • •An introduction to the SENTRY surveillance network.
  • ANONYMOUS: Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections - Los Angeles county, California, 2002-2003. MMWR (2003) 52:88.
  • MOY JA, CALDWELL-BROWN D, LIN AN, PAPPA KA, CARTER DM: Mupirocin-resistant Staphylococcus aureus after long-term treatment of patients with epidermolysis bullosa. Am. Acad. Dermata (1990) 22:893–895.
  • MOELLERING RC JR: Linezolid: the first oxazolidinone antimicrobial. Ann. Inter. Med. (2003) 138:135–142.
  • EDLUND C, OH H, NORD CE: In vitro activity of linezolid and eperezolid against anaerobic bacteria. Clin. Microbial. Infect. (1999) 5:51–53.
  • GOLDSTEIN EJC, CITRON DM, MERRIAM CV: Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob. Agents Chemother. (1999) 43:1469–1474.
  • LEACH TS, SCHAVER RJ, TODD WM et al.: Clinical efficacy of linezolid for complicated skin and soft tissue infections caused by MRSA. Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, USA (2000) (Abstract 60).
  • WILKE RJ, LI ZJ, RITTENHOUSE BE et al: Linezolid's effects on early hospital discharge in hospitalized patients with complicated skin and soft tissue infections under varying rates of methicillin-resistant Staphylococcus infection: analysis of results from two randomized clinical trials. Program and abstracts of the 4Gth Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (2000) (Abstract 112).
  • ALLINGTON DR RIVEY MP: Quinupristin/dalfopristin: a therapeutic review. Clin. The]: (2001) 23:24–44.
  • LAMB HM, FIGGETT DP, FAULDS D: Quinupristin/dalfopristin: a review of its use in the management of serious Gram-positive infections. Drugs (1999) 58:1061–1097.
  • PERRY CM, ORMROD D, HURST M, ONRUST SV: Gatifloxacin: a review of its use in the management of bacterial infections. Drugs (2002) 62:169–207.
  • LOWE MN, LAMB HM: Gemifloxacin. Drugs (2000) 59:1137–1147.
  • MUIJSERS RB, JARVIS B: Mwdfloxacin in uncomplicated skin and skin structure infections. Drugs (2002) 62:967–973.
  • •A brief but thorough overview of moxifloxacin that concentrates on its role in treating SSSIs.
  • BARMAN BALFOUR JA, LAMB HM: Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs (2000) 59:115–139.
  • GOLDSTEIN EJC, CITRON DM, MERRIAM CV, WARREN Y, TYRRELL K: Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob. Agents Chemother. (2000) 44:2747–2751.
  • AMINIMANIZANI A, BERINGER P, JELLIFFE R: Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin. Pharmacokinet. (2001) 40:169–187.
  • WISE R GEE T, ANDREWS J, MARSHALL G: The pharmacokinetics and inflammatory fluid penetration of gemifloxacin. Program and abstracts of the 40h Interscience Conference on Antimicrob. Agents Chemother. Toronto, Ontario, Canada (2000) (Abstract 657).
  • MULLER M, STASS H, BRUNNER M: Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob. Agents Chemother. (1999) 43:2345–2349.
  • WISER, ANDREWS JM, MARSHALL G: Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob. Agents Chemother. (1999) 43:1508–1510.
  • LEAL DEL ROSAL P, FABIAN G, VICK-FRAGOSO R et al.: Efficacy and safety of moxifloxacin (MXF) versus cephalexin (with or without metronidazole) in the treatment of mild to moderate uncomplicated skin and skin structure infections (uSSSI). Program and abstracts of the 39h Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA (1999) (Abstract 716).
  • LEAL DEL ROSAL P, MARTINEZ R, FABIAN G et al.: Efficacy and safety of moxifloxacin versus cephalexin in the treatment of mild to moderate uncomplicated skin and soft tissue infections (USSI). Proceedings of the 21k International Congress of Chemotherapy Birmingham, UK (1999) (Abstract P493).
  • GUAY DRP: Oritavancin and tigecycline: promising investigational antimicrobials for multiresistant Gram-positive bacteria. Phannacotherapy (2003) (Submitted).
  • CARSON CF, RILEY TV: Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia. Appl. Bacteria (1995) 78:264–269.
  • NELSON RRS: In vitro activities of five plant essential oils against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Antimicrob. Chemother. (1997) 40:305-306 (Letter).
  • CARSON CF, COOKSON BD, FARRELLY HD, RILEY TV: Susceptibility of methicillin-resistant Staphylococcus aureus to the essential oil of Melaleuca alternifolia. Antimicrob. Chemother. (1995) 35:421–424.
  • ELSOM GKF, HIDE D: Susceptibility of methicillin-resistant Staphylococcus aureus to tea tree oil and mupirocin. Antimicrob. Chemother. (1999) 43:427-428 (Letter).
  • CARSON CF, RILEY TC, COOKSON BD: Efficacy and safety of tea tree oil as a topical antimicrobial agent. Hosp. Infect. (1998) 40:175–178.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.